Status:
RECRUITING
Remimazolam vs. Propofol: Impact on Postoperative Delirium in Neurosurgical Patients
Lead Sponsor:
Samsung Medical Center
Conditions:
Postoperative Delirium
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The investigator aimed to evaluate the incidence of postoperative delirium after remimazolam-based total intravenous anestheisa (TIVA) compared to the propofol-based TIVA in patients undergoing neuros...
Detailed Description
Remimazolam, a short-acting benzodiazepine, has recently gained approval for use in the induction and maintanance of general anesthesia. In American Society of Anesthesiologists (ASA) physical status ...
Eligibility Criteria
Inclusion
- American society of anesthesia (ASA) class I - III
Exclusion
- Severe respiratory, cardiovascular, or hepatic disease (child-pugh C)
- Dependency on psychiatric drugs or alcohol
- Severe sensory impairments that impede communication
- Preoprative delirium
- Hypersensitivity, allergies, or contraindication to the study drugs.
Key Trial Info
Start Date :
January 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
696 Patients enrolled
Trial Details
Trial ID
NCT06115031
Start Date
January 29 2024
End Date
December 31 2026
Last Update
April 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 06351